- Home
- PLBC vs IMRX Comparison
PLBC vs IMRX Comparison
Compare PLBC & IMRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | PLBC | IMRX |
|---|---|---|
| Founded | 1980 | 2008 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance Companies | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 320.9M | 366.1M |
| IPO Year | 2005 | 2021 |
Fundamental Metrics
Financial Performance| Metric | PLBC | IMRX |
|---|---|---|
| Price | $44.54 | $4.66 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 3 | 5 |
| Target Price | ★ $55.00 | $17.20 |
| AVG Volume (30 Days) | 14.8K | ★ 2.8M |
| Earning Date | 01-16-2026 | 11-12-2025 |
| Dividend Yield | ★ 2.69% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 4.23 | N/A |
| Revenue | ★ $89,868,000.00 | N/A |
| Revenue This Year | $21.11 | N/A |
| Revenue Next Year | $16.11 | N/A |
| P/E Ratio | $10.57 | ★ N/A |
| Revenue Growth | ★ 12.51 | N/A |
| 52 Week Low | $38.71 | $1.10 |
| 52 Week High | $49.47 | $10.08 |
Technical Indicators
Market Signals| Indicator | PLBC | IMRX |
|---|---|---|
| Relative Strength Index (RSI) | 53.97 | 37.32 |
| Support Level | $43.45 | $6.26 |
| Resistance Level | $45.02 | $8.48 |
| Average True Range (ATR) | 0.90 | 0.63 |
| MACD | -0.16 | -0.11 |
| Stochastic Oscillator | 45.62 | 11.81 |
Price Performance
Historical ComparisonAbout PLBC Plumas Bancorp
Plumas Bancorp provides various banking products and services in Northeastern California and Northwestern Nevada. It provides various deposit products such as checking, interest-bearing checking, business sweep, public funds sweep, savings, time deposit, and retirement accounts. The bank's loan portfolio consists of commercial real estate loans; commercial and industrial loans; consumer loans; agricultural loans; residential real estate loans, and construction and land development loans. The bank generates revenue from loans and investment securities in its portfolio and, to a lesser extent, service fees.
About IMRX Immuneering Corporation
Immuneering Corp is a biopharmaceutical company. It is focused on improving patient outcomes across a spectrum of debilitating oncologic and neurologic diseases by applying deep knowledge of translational bioinformatics to every stage of the drug development process. The company's proprietary computational Disease Cancelling Technology platform enables Immuneering's drug discovery programs. The company also provides unparalleled computational biology capabilities to pharmaceutical and biotechnology companies.